Amneal Pharmaceuticals (AMRX) announced that the FDA has tentatively approved the company’s abbreviated new drug application for beclomethasone dipropionate HFA inhalation aerosol. The product is the generic equivalent of Qvar inhalation aerosol.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Mycophenolate Pregnancy Registry: Key Insights for Investors
- Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?
- Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection
- Amneal treatment of known or suspected cyanide poisoning granted orphan status
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR